Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-078614
Filing Date
2025-08-14
Accepted
2025-08-14 16:15:34
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 13427
  Complete submission text file 0001104659-25-078614.txt   15180
Mailing Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129
Business Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129 415-489-9980
Redmile Group, LLC (Filed by) CIK: 0001425738 (see all company filings)

EIN.: 208592298 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address BIOPOLE ROUTE DE LA CORNICHE 3B EPALINGES V8 1066
Business Address BIOPOLE ROUTE DE LA CORNICHE 3B EPALINGES V8 1066 41 21 653 02 00
ADC Therapeutics SA (Subject) CIK: 0001771910 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91517 | Film No.: 251219336
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)